Bone Mineral Density and Vitamin D Status in Patients with Autoimmune Polyglandular Syndromes: A Single Tertiary Care Center Experience

Abstract

Immunological abnormalities, the resulting endocrinopathies, and their treatments may impact bone health and 25-hydroxyvitamin D (25-OHD) in patients with autoimmune polyglandular syndromes (APS). Several etiologies contribute to increased risk for low bone mineral density (BMD), including vitamin D deficiency. This study evaluated the vitamin D level and BMD of patients with APS. We performed a cross-sectional study on 44 patients with APS and 55 age and gender-matched control subjects. Among patients with APS, 14 were classified as APS-2 [Addison’s disease (AD)+autoimmune thyroid disease (ATD) and/or type 1 diabetes(T1D)]. In contrast, the other 30 were APS-3 (ATD+T1D+other autoimmune diseases). Serum samples were analyzed for vitamin D levels. The lumbar spine and femoral neck BMD were measured by dual X-ray absorptiometry. Z-scores were obtained by comparison with age- and gender-matched average values (both patients and controls). The accepted normal levels were Z-score>–1 and 25-OHD>30 ng/ml. Patients with APS showed 25-OHD levels and BMD significantly lower than healthy controls (p<0.001 and p<0.05, respectively). The highest prevalence of abnormal BMD was observed in the APS-2 subgroup (13 out of 14 patients, 92.6%). Identifying and treating vitamin D deficiency and low BMD is critical in APS patients. The fact that the significant endocrine component of APS-2 is AD, and these patients receive chronic long-term glucocorticoid therapy can be shown as the reason for this result. However, more extensive prospective controlled studies are needed to confirm these findings.

Key words

autoimmune polyglandular syndrome - vitamin D deficiency - low bone mineral density - Addison’s disease

Publikationsverlauf

Eingereicht: 11. September 2023

Angenommen nach Revision: 06. November 2023

Accepted Manuscript online:
06. November 2023

Artikel online veröffentlicht:
06. Dezember 2023

• References

• 1 Kahaly GJ, Frommer L. Polyglandular autoimmune syndromes. J Endocrinol Invest 2018; 41: 91-98
• 2 Pham-Dobor G, Hanák L. Hegyi Pet al. Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III. J Endocrinol Invest 2020; 43: 1-9
• 3 Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome type 2: the tip of an iceberg?. Clin Exp Immunol 2004; 137: 225-233
• 4 Bellastella G, Maiorino MI, Petrizzo M. et al. Vitamin D and autoimmunity: what happens in autoimmune polyendocrine syndromes?. J Endocrinol Invest 2015; 38: 629-633
• 5 Altieri B, Muscogiuri G, Barrea L. et al. Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. Rev Endocr Metab Disord 2017; 18: 335-346
• 6 Goswami R, Marwaha RK, Gupta N. et al. Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br J Nutr 2009; 102: 382-386
• 7 Ziaei-Kajbaf T, Aminzadeh M, Fatahinezhad E. et al. Vitamin D status in diabetic children and adolescents. Diabetes Metab Syndr 2018; 12: 849-852
• 8 Ramagopalan SV, Goldacre R, Disanto G. et al. Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: record-linkage studies. BMC Med 2013; 11: 171
• 9 Lopez ER, Zwermann O, Segni M. et al. A promoter polymorphism of the CYP27B1 gene is associated with Addison’s disease, Hashimoto’s thyroiditis, Graves’ disease and type 1 diabetes mellitus in Germans. Eur J Endocrinol 2004; 151: 193-197
• 10 Shah VN, Harrall KK, Shah CS. et al. Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos Int 2017; 28: 2601-2610
• 11 Husebye ES, Pearce SH, Krone NP. et al. Adrenal insufficiency. Lancet 2021; 397: 613-629
• 12 Hu Y, Li X, Yan X. et al. Bone mineral density spectrum in individuals with type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes. Diabetes Metab Res Rev 2021; 37: e3390
• 13 Delitala AP, Scuteri A, Doria C. Thyroid hormone diseases and osteoporosis. J Clin Med 2020; 9: 1034
• 14 Holick MF, Binkley NC, Bischoff-Ferrari HA. et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930
• 15 Schousboe JT, Shepherd JA, Bilezikian JP. et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 2013; 16: 455-466
• 16 Crabtree NJ, Arabi A, Bachrach LK. et al. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. J Clin Densitom 2014; 17: 225-242
• 17 Zawadzka K, Matwiej K, Sokołowski G. et al. Vitamin D status and its associations with clinical and laboratory parameters in patients with Addison’s disease. Folia Med Cracov 2021; 61: 65-78
• 18 Schulz J, Frey KR, Cooper MS. et al. Reduction in daily HC dosage improves bone health in primary adrenal insufficiency. Eur J Endocrinol 2016; 174: 531-538
• 19 Warriner AH, Saag KG. Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids. Curr Opin Endocrinol Diabetes Obes 2013; 20: 510-516
• 20 Hardy RS, Zhou H, Seibel MJ. et al. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev 2018; 39: 519-548
• 21 Vaňuga P, Ságová I. Introduction: patients with primary adrenal insufficiency receive long-term glucocorticoid replacement therapy, which may cause osteoporosis. Vnitr Lek 2021; 67: 264-269
• 22 Løvås K, Gjesdal CG, Christensen M. et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur J Endocrinol 2009; 160: 993-1002
• 23 Leelarathna L, Breen L, Powrie JK. et al. Co-morbidities, management and clinical outcome of autoimmune Addison’s disease. Endocrine 2010; 38: 113-117
• 24 Koetz KR, Ventz M, Diederich S. et al. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012; 97: 85-92
• 25 Schulz J, Frey KR, Cooper MS. et al. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur J Endocrinol 2016; 174: 531-538
• 26 Cohen A. Premenopausal osteoporosis. Endocrinol Metab Clin North Am 2017; 46: 117-133
• 27 Kumar V, Rajadhyaksha M, Wortsman J. Celiac disease-associated autoimmune endocrinopathies. Clin Diagn Lab Immunol 2001; 8: 678-685
• 28 Akkurt Kocaeli A, Cander S, Öz Gül Ö. et al. Serological screening for celiac disease and gastrointestinal absorption disorders in patients with autoimmune endocrine diseases. Horm Metab Res 2023; 55: 781-787
• 29 Ganji R, Moghbeli M, Sadeghi R. et al. Prevalence of osteoporosis and osteopenia in men and premenopausal women with celiac disease: a systematic review. Nutr J 2019; 18: 9
• 30 Chevalley T, Rizzoli R. Acquisition of peak bone mass. Best Pract Res Clin Endocrinol Metab 2022; 36: 101616
• 31 Garvey ME, Shi L, Lichtenstein AH. et al. Association of bone mineral density with lean mass, fat mass, and physical activity in young overweight and obese women. Int J Exerc Sci 2022; 15: 585-598